2007 New Frontiers in Cancer Detection & Diagnosis Gordon Conference

描述（由申请人提供）：早期癌症的准确检测对于通过开发癌症特异性干预措施来改善患者护理至关重要，以避免侵袭、转移性播散和随后的晚期疾病。 国家癌症研究所的癌症预防部门已经建立了早期检测研究网络（EDRN），这是一个多机构联盟，致力于改进在早期阶段检测癌症的方法。 EDRN已发展成为一个国际研究计划，支持和促进广泛的研究活动，特别是发现，开发和验证用于准确检测早期癌症的分子生物标志物。 凭借尖端技术，多学科专家正在EDRN中共同努力，以实现改善患者护理的使命。 这一拟议的2007年戈登癌症检测和诊断新前沿会议的目的是将具有基础、转化和临床肿瘤学专门知识的初级和高级医生和科学家以及计算生物学、生物技术和信息学专家聚集在一个有利于建立伙伴关系的独特培养环境中。 这样的设置提供了一个独特的机会和场所，激烈的讨论和癌症研究的评估，建立研究重点的优点，并通过新建立的合作领域的进步。 在专注于联合生物学，肿瘤学和技术的氛围中，医生和科学家将共同努力开发癌症生物标志物的潜在临床应用，以改善患者护理。 为了支持会议的总体目标和目的，该计划分为九个科学全体会议部分，题为：早期癌症检测生物学I，早期癌症生物学II，生物标志物发现的启用技术，基于基因组学的诊断生物标志物，作为生物标志物的组学：糖组学，脂质组学，代谢组学，蛋白质组学，表位组学和免疫组学，处于十字路口的生物标志物：临床现实检查，基于数据挖掘的生物标志物发现，以及四个海报会议。

DESCRIPTION (provided by applicant): The accurate detection of early stage cancer is critical to improve patient care by developing cancer specific interventions to avert invasion metastatic dissemination and subsequent advanced disease. The National Cancer Institute's Division of Cancer Prevention has established the Early Detection Research Network (EDRN), a multi-institutional consortium endeavoring to improve methods for detecting cancer at its earliest stage. The EDRN has developed into an international research program of substantial charge and scope that supports and facilitates a broad spectrum of research activities, particularly the discovery, development and validation of molecular biomarkers for the accurate detection of early stage cancer. Armed with cutting-edge technologies, multidisciplinary experts are working together in the EDRN to fulfill the mission of improving patient care. The purpose of this proposed 2007 Gordon Conference on New Frontiers in Cancer Detection and Diagnosis is to bring together junior and senior physicians and scientists with expertise in basic, translational and clinical oncology, as well as experts in computational biology, biotechnology and informatics in a unique nurturing environment conducive to forging partnerships. Such a setting provides a unique opportunity and venue for intense discussion and evaluation of cancer research, establishing the merit of research priorities, and advancement of the field through newly established collaborations. In an atmosphere focused on uniting biology, oncology and technology, physicians and scientists will work together to develop potential clinical applications of cancer biomarkers to improvement of patient care. To support the overall goals and objectives of the conference, the program is organized in nine scientific plenary sections entitled: Biology of Early Cancer Detection I, Biology of Early Cancer II, Enabling Technologies for Biomarker Discovery, Genomics-Based Diagnostic Biomarkers, Omics as Biomarkers: Glycomics, Lipidomics, Metabolomics, State of Proteomics, Epitomics and Immunomics, Biomarkers at a Crossroads: A Clinical reality Check, and Data Mining Based Biomarker Discovery, together with four poster sessions.